Form 4: Enliven Therapeutics Director Richard Heyman Sells Shares
SEC Filing Form 4
Richard A. Heyman, a director at Enliven Therapeutics, sold shares of the company's common stock in multiple transactions on April 11 and April 15, 2024, according to a Form 4 filing with the SEC.
Summary
- Richard A. Heyman, a director of Enliven Therapeutics, Inc. (ELVN), filed a Form 4 with the SEC indicating changes in beneficial ownership.
- On April 11, 2024, Heyman sold 5,045 shares of common stock at a weighted average price of $25.0306 per share.
- Additional sales occurred on April 15, 2024, with 1,190 shares sold at a weighted average price of $19.9403 and 80 shares sold at a weighted average price of $20.6773.
- Following these transactions, Heyman directly owns 137,155 shares of common stock.
- Heyman also indirectly owns 28,567 shares through RAHD Capital LLC and 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust.
- The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on July 17, 2023.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports insider selling under a pre-arranged plan. It doesn't inherently indicate positive or negative company performance.
Negatives
- A director selling shares could be perceived negatively by investors.
Risks
- Insider selling can sometimes signal a lack of confidence in the company's future prospects, although this sale was conducted under a pre-arranged trading plan.
Industry Context
Insider trading activity is closely monitored in the pharmaceutical industry to ensure fair market practices and investor confidence.
Comparison to Industry Standards
- Monitoring insider trading activity is a standard practice across publicly traded companies, especially in the biotech and pharmaceutical sectors.
- Comparing the trading patterns of Enliven Therapeutics' insiders to those of similar companies like Relay Therapeutics or Black Diamond Therapeutics could provide insights into market sentiment.
Stakeholder Impact
- Shareholders may react to the news of insider selling, although the existence of a pre-arranged trading plan mitigates potential concerns.
Key Dates
| Date | Description |
|---|---|
| 2016-11-01 | Date of the Richard A. Heyman and Anne E. Daigle Trust |
| 2023-07-17 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| 2024-04-11 | Date of first reported transaction |
| 2024-04-15 | Date of second reported transaction |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.